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Atrial fibrillation (AF) confers a 5-fold increase 
in the risk of stroke and thromboembolism and 
a 2-fold increase in mortality due mainly to stroke 
and heart failure. Oral anticoagulation with well 
managed dose adjusted vitamin K antagonist or 
a non-vitamin K antagonist highly effective in 
reducing this risk. Unfortunately, despite oral 
thromboprophylaxis, adverse cardiovascular (CV) 
events in AF patients is approximately 4% [1].
In the current issue of “Cardiology Journal”, 
Szymański et al. [2] report a higher prevalence of 
erectile dysfunction (ED) among older patients 
with increasing thromboembolic risk. In its present 
form the paper does little more than highlight the 
association between ED and older age since this 
is the only component of either the CHADS2 or 
CHA2SD2-VASc scores that is significantly differ-
ent between older patients (defined as ≥ 65 by 
the authors) with and without ED and therefore 
driving the outcome in this population. In the 
younger group (defined as < 65 by the authors), 
the age difference is not significant enough to 
create a difference in the overall CHADS2 or 
CHA2SD2-VASc risk score between patients with 
and without ED. Also notable is the absence of 
a multivariate analysis to adjust for the difference 
in waist circumference since several measures of 
adiposity are negatively correlated with endothelial 
function and waist circumference reduction has 
been shown to be associated with improved en-
dothelial function in certain groups [3]. Moreover, 
increased adiposity creates a procoagulant state 
and is linked to over expression of proinflamma-
tory markers of endothelial dysfunction such as 
fibrinogen, C reactive protein and von Willebrand 
Factor (vWF), possibly via a mechanism involving 
the CD40 ligand [4, 5]. Furthermore, whilst it may 
be appropriate to consider ED as an additional 
marker of a prothrombotic state, it is difficult to 
see how a diagnosis of ED would influence the 
clinical decision-making process in patients over 
65 with AF (other than to prompt treatment of the 
ED itself), who would already qualify for oral anti-
coagulation according to international guidelines. 
Also, it would seem counterintuitive that ED would 
add much predictive power to the CHA2SD2-VASc 
score given that women are at a higher overall risk 
of thromboembolic stroke than men for reasons 
which are unclear but may be related to hormone 
therapy and sex differences in hemodynamics and 
CV remodeling [6]. ED, like stroke, is an outcome 
of cumulative vascular risk factors including AF.
The CHADS2 and the CHA2SD2-VASc scores 
have been shown to predict to thromboembolic 
risk in patients with AF, with the CHA2SD2-VASc 
score improving risk stratification at the ‘low risk’ 
end of the spectrum [7]. In addition, Roldán et al. 
[8] have previously reported a significant positive 
correlation between vWF and the CHADS2 score 
supporting the association between increasing 
thromboembolic risk and vascular dysfunction.
The inherent threat to vascular health as-
sociated with the presence of these risk factors is 
common to all vascular territories so it is perhaps 
not surprising that accumulation of thromboem-
bolic risk factors is associated with ED — itself, an 
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is well recognised in AF [9]. Despite the analyti-
cal shortcomings the paper raises an interesting 
mechanistic hypothesis regarding occlusion of the 
penile arteries by microthrombi according to the 
artery size hypothesis. This is certainly plausible 
in terms of Virchow’s triad of thrombogenesis 
since AF leads directly to blood stasis and hyper-
coagulability within the left atrium (LA). Moreover, 
evidence from Lim et al. [10] has demonstrated that 
thrombin generation occurs in humans to a greater 
extent in the LA in response to AF thus supporting 
the potential for microthrombi embolisation.
Over the last decade, it has become increas-
ingly apparent that AF is also associated with 
systemic inflammation and endothelial dysfunc-
tion irrespective of traditional CV risk factors. 
For example, permanent AF has been shown to 
be an independent predictor of impaired brachial 
artery flow mediated dilatation [11] whilst plasma 
levels of soluble E-selectin and vWF are raised 
in all forms of AF [12]. Furthermore, in porcine 
models, rapid atrial tachycardia (simulated by pac-
ing) has been shown to enhance the local release 
of vasoactive substances such as angiotensin II 
[13], whilst also down-regulating the expression 
of nitric oxide synthase (NOS) expression and sub-
sequent nitric oxide production [14]. This not only 
creates oxidative stress leading to subsequent left 
ventricular microvascular flow abnormalities but 
also leads to loss of the antithrombotic properties 
of NOS, thus contributing to hypercoagulability. In 
humans, whilst rapid atrial rates increase platelet 
activation (particularly in the LA), the additive ef-
fects of endothelial dysfunction and inflammation 
seem to occur only in the presence of AF [10]. 
Conversely, both macrovascular and microvascular 
indices of endothelial function have been found to 
predict atrial high rate episodes in patients with 
dual chamber pacemakers [15]. It is therefore 
likely that a self-perpetuating phenomenon exists 
(as with many scenarios in medicine) whereby 
continued AF leads to declining endothelial func-
tion which further contributes to continuation of 
AF. Importantly, improved endothelial function 
has been demonstrated after restoration of sinus 
rhythm in AF patients with some studies showing 
an increase in circulating endothelial progenitor 
cells post cardioversion suggesting a role for these 
reparative cells [16].
Inflammation is an important potential link 
between AF and impaired endothelial function 
since activated inflammatory cells and mediators 
such as tumor necrosis factor a, interleukin (IL)-2, 
IL-6, IL-8, and/or monocyte chemoattractant 
protein (MCP)-1, that develop during arrhythmia 
promote endothelial injury and confer a prothrom-
botic state [1].
Recently, there has been considerable pro-
gress in identifying genetic variants of CV disease. 
Micro RNAs (miRNA) are endogenously produced 
small molecules that specifically bind to miRNA 
and have assumed a fundamental role in the gene 
expression regulatory network [1]. They have been 
linked to atherogenesis, induction and perpetuation 
of AF, and, more recently, described as prognostic 
markers of adverse CV events in anticoagulated 
AF patients [1].
Whether or not ED is predictor of stroke in AF 
patients remains to be seen. There are conflicting 
studies in non AF patients. The pathophysiology 
by which this common arrhythmia fulfils the com-
ponents of Virchow’s triad is multi-faceted and 
due, in part, to the complex structural and electri-
cal atrial remodeling that occurs in this condition. 
Micro RNA may represent a therapeutic target for 
reducing thromboembolic risk in the future but at 
the moment it is early days.
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